DV
Dividend Vision

ACXP — Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals LLC (ACXP)

Total return is -99.1% over the past 5.1 years, 193.8 points behind SPY at 94.7%. Its deepest 1-year drawdown was 83.3%.

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel antibiotics to treat bacterial infections, with its lead candidate ibezapolstat in Phase 2b trials for clostridium difficile infections and a secondary program, ACX-375C, targeting gram-positive bacteria including MRSA and VRE. The company does not currently distribute dividends. Acurx appeals to investors seeking exposure to early-stage biotech development rather than current income, as the company is pre-revenue and focused on advancing its pipeline toward regulatory approval.

ACXP key facts

Asset type
Stock
Asset class
Equity
Inception date
06/25/2021
Last close
$1.40
Market cap
$6,661,493
Average volume
613887.0
Beta
-2.045
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.79